The Pharmacy Times® Biosimilars Resource Center is a comprehensive resource for clinical news and expert insights on issues related to biosimilar drugs, a biological product that is highly similar to a reference biologic for which there are no clinically meaningful differences in terms of safety, purity, and efficacy.
May 6th 2024
Study participants’ overall satisfaction with a mandatory nationwide adalimumab transition in New Zealand varied but was generally low.
Expert Discusses Formulary Changes in Oncology Biosimilars at AMCP Annual Meeting
April 7th 2022In an interview with Pharmacy Times®, Eric Tichy, PharmD, MBA, BCPS, FAST, FCCP, Vice Chair of Pharmacy/Formulary at Mayo Clinic, discusses some formulary trends in biosimilars at the Academy of Managed Care Pharmacy Annual Meeting.
Watch
Expert: We Are Now in a Time When There Is ‘Widespread Adoption of Biosimilars’ in Health Care
March 21st 2022Shannon Hough, director of ClinReview and Clinical Content for McKesson, discusses the advantages of including pharmacy staff as part of the care team when payer or drug availability challenges arise.
Watch
FDA Approves First Ophthalmology Biosimilar for Neovascular Age-Related Macular Degeneration
September 20th 2021An anti-vascular endothelial growth factor therapy, ranibizumab prevents vision loss in patients with retinal vascular disorders, which can cause irreversible blindness or visual impairments in adults.
Read More
FDA Approves Insulin Glargine-yfgn as First Interchangeable Biosimilar Insulin Product for Diabetes
July 29th 2021Insulin glargine-yfgn is the first interchangeable biosimilar product for the treatment of diabetes approved in the United States, which can provide patients with alternative, equally effective options for treating diabetes that could be more cost effective.
Read More